Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma-Activated Saline Solution in Bladder Cancer
NCT07272603Phase 1Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
Phase 1, open-label, single-arm trial of plasma-activated saline in bladder cancer, sponsored by Qilu Hospital of Shandong University. Primary endpoint: Change in Tumor Size at Day 7. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
plasma-activated saline
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT07272603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272603.